# US 2021/0171980 A1 · Compounds for improved viral transduction

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171980 A1
- Document ID: US20210171980A1
- Status: Published application
- Kind: A1
- Application number: 17/125,930
- Filed: 2020-12-17
- Published: 2021-06-10
- Earliest claimed: 2011-09-30
- Assignees: bluebird bio, Inc.
- Applicants: bluebird bio, Inc.
- Inventors: Garrett Collins Heffner; Abraham Isaac Bassan
- Web page: https://patentgrep.com/patent/US20210171980A1

## CPC

- C12N 15/86: Viral vectors
- A61K 38/46: Hydrolases (3)
- A61P 5/38: of the suprarenal hormones
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/06: Antianaemics
- C12N 5/0647: {Haematopoietic stem cells; Uncommitted or multipotent progenitors}
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- C12N 15/867: Retroviral vectors
- C12N 2501/02: Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
- C12N 2510/00: Genetically modified cells
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N 2810/6081: rhabdoviridae, e.g. VSV
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides methods and compositions for improving efficacy of viral transduction of cells. More particularly, the present invention provides methods and materials useful for safely and reliably improving the efficiency of methods and materials useful for safely and reliably improving the efficiency of methods for transducing cells, such as human hematopoietic stem cells (HSC), with viruses and/or viral vectors. The compositions and methods are useful for therapeutic indications amenable to treatment with hematopoietic stem cell gene therapies.

## Claims

### Claim at position 1

-28. (canceled)

### Claim 29

A method for increasing the lentiviral vector transduction efficiency of human CD34+ hematopoietic stem or progenitor cells comprising:
contacting the human CD34+ hematopoietic stem or progenitor cells with a culture medium comprising a lentiviral vector and prostaglandin E2 (PGE2), 16,16-dimethyl PGE2, or an analogue thereof, ex vivo
wherein the lentiviral vector transduction efficiency is increased in the human CD34+ hematopoietic stem or progenitor cells contacted with the culture medium compared to the lentiviral vector transduction efficiency of human CD34+ hematopoietic stem or progenitor cells contacted with a culture medium comprising the lentiviral vector in the absence of PGE2, 16,16-dimethyl PGE2, or an analogue thereof.

### Claim 30 (depends on 29)

The method of claim 29, wherein the human CD34+ hematopoietic stem or progenitor cells are human CD34+ hematopoietic stem cells.

### Claim 31 (depends on 29)

The method of claim 29, wherein the human CD34+ hematopoietic stem or progenitor cells are human CD34+ hematopoietic progenitor cells.

### Claim 32 (depends on 29)

The method of claim 29, wherein
a) at least 50% of the human CD34+ hematopoietic stem or progenitor cells are transduced;
b) at least 75% of the human CD34+ hematopoietic stem or progenitor cells are transduced; or
c) at least 90% of the human CD34+ hematopoietic stem or progenitor cells are transduced.

### Claim 33 (depends on 29)

The method of claim 29, wherein the medium further comprises a histone deacetylase (HDAC) inhibitor.

### Claim 34 (depends on 33)

The method of claim 33, wherein the HDAC inhibitor is selected from the group consisting of: Trichostatin A (TSA), valproic acid (VPA), sodium butyrate, suberoylanilide hydroxamic acid (SAHA), sodium phenylbutyrate, depsipeptide, trapoxin (TPX), cyclic hydroxamic acid-containing peptide 1 (CHAP1), MS-275, LBH589, and PXD-101.

### Claim 35 (depends on 29)

The method of claim 29, wherein the lentiviral vector is derived from a Human immunodeficiency virus (HIV) virus.

### Claim 36 (depends on 29)

The method of claim 29, wherein the lentiviral vector is pseudotyped with a vesicular stomatitis virus G-protein (VSV-G) envelope protein.

### Claim 37 (depends on 29)

The method of claim 29, wherein the human CD34+ hematopoietic stem or progenitor cells are contacted with the culture medium comprising the lentiviral vector and PGE2, 16,16-dimethyl PGE2, or an analogue thereof for at least four hours or for at least twenty-four hours.

### Claim 38 (depends on 29)

The method of claim 29, wherein the lentiviral vector comprises:
a) a left (5′) lentiviral long terminal repeat (LTR) comprising a heterologous promoter;
b) an expression control sequence operably linked to a gene of interest; and
c) a right (3′) lentiviral SIN LTR.

### Claim 39 (depends on 29)

The method of claim 29, wherein the lentiviral vector comprises:
a) a left (5′) HIV-1 LTR comprising a CMV promoter;
b) a Psi packaging sequence (Ψ+);
c) an HIV-1 central polypurine tract/DNA flap (cPPT/FLAP);
d) a rev response element (RRE);
e) a β-globin promoter and a β-globin locus control region (LCR) operably linked to a gene of interest; and
f) a right (3′) lentiviral SIN LTR that comprises
i) one or more insulator elements, or
ii) a rabbit β-globin polyA (rβgpA) sequence.

### Claim 40 (depends on 29)

The method of claim 29, wherein the lentiviral vector comprises:
a) a left (5′) HIV-1 LTR comprising a CMV promoter;
b) a Psi (Ψ+) packaging signal;
c) a cPPT/FLAP;
d) an RRE;
e) a myeloproliferative sarcoma virus enhancer, negative control region deleted, d1587rev primer-binding site substituted (MND) promoter, operably linked to a polynucleotide encoding a human ATP-binding cassette, sub-family D, member 1 (ABCD1) polypeptide;
f) a right (3′) HIV-1 SIN LTR; and
g) a rβgpA sequence.

### Claim 41

A method for increasing the lentiviral transduction efficiency of human CD34+ hematopoietic stem or progenitor cells comprising:
contacting the human CD34+ hematopoietic stem or progenitor cells with a culture medium comprising a lentiviral vector and PGE2, ex vivo
wherein the lentiviral transduction efficiency is increased in the human CD34+ hematopoietic stem or progenitor cells contacted with the culture medium compared to the lentiviral transduction efficiency of human CD34+ hematopoietic stem or progenitor cells contacted with a culture medium comprising the lentiviral vector in the absence of PGE2.

### Claim 42 (depends on 41)

The method of claim 41, wherein
a) at least 50% of the human CD34+ hematopoietic stem or progenitor cells are transduced;
b) at least 75% of the human CD34+ hematopoietic stem or progenitor cells are transduced; or
c) at least 90% of the human CD34+ hematopoietic stem or progenitor cells are transduced.

### Claim 43 (depends on 41)

The method of claim 41, wherein the lentiviral vector is derived from an HIV virus.

### Claim 44 (depends on 41)

The method of claim 41, wherein the lentiviral vector is pseudotyped with a VSV-G envelope protein.

### Claim 45 (depends on 41)

The method of claim 41, wherein the human CD34+ hematopoietic stem or progenitor cells are contacted with the culture medium comprising the lentiviral vector and PGE2 for at least four hours or for at least twenty-four hours.

### Claim 46 (depends on 41)

The method of claim 41, wherein the lentiviral vector comprises:
a) a left (5′) lentiviral LTR comprising a heterologous promoter;
b) an expression control sequence operably linked to a gene of interest; and
c) a right (3′) lentiviral SIN LTR.

### Claim 47 (depends on 41)

The method of claim 41, wherein the lentiviral vector comprises:
a) a left (5′) HIV-1 LTR comprising a CMV promoter;
b) a Psi packaging sequence (Ψ+);
c) an HIV-1 cPPT/FLAP;
d) an RRE;
e) a β-globin promoter and a β-globin LCR operably linked to a gene of interest; and
f) a right (3′) lentiviral SIN LTR that comprises
i) one or more insulator elements, or
ii) a rβgpA sequence.

### Claim 48 (depends on 41)

The method of claim 41, wherein the lentiviral vector comprises:
a) a left (5′) HIV-1 LTR comprising a CMV promoter;
b) a Psi (Ψ+) packaging signal;
c) a cPPT/FLAP;
d) an RRE;
e) an MND promoter, operably linked to a polynucleotide encoding a human ABCD1 polypeptide;
f) a right (3′) HIV-1 SIN LTR; and
g) a rβgpA sequence.

### Claim 49

A method for increasing the lentiviral transduction efficiency of human CD34+ hematopoietic stem or progenitor cells comprising:
contacting the human CD34+ hematopoietic stem or progenitor cells with a culture medium comprising a lentiviral vector and 16,16-dimethyl PGE2, ex vivo
wherein the lentiviral transduction efficiency is increased in the human CD34+ hematopoietic stem or progenitor cells contacted with the culture medium compared to the lentiviral transduction efficiency of human CD34+ hematopoietic stem or progenitor cells contacted with a culture medium comprising the lentiviral vector in the absence of 16,16-dimethyl PGE2.

### Claim 50 (depends on 49)

The method of claim 49, wherein
a) at least 50% of the human CD34+ hematopoietic stem or progenitor cells are transduced;
b) at least 75% of the human CD34+ hematopoietic stem or progenitor cells are transduced; or
c) at least 90% of the human CD34+ hematopoietic stem or progenitor cells are transduced.

### Claim 51 (depends on 49)

The method of claim 49, wherein the lentiviral vector is derived from an HIV-1 virus.

### Claim 52 (depends on 49)

The method of claim 49, wherein the lentiviral vector is pseudotyped with a VSV-G envelope protein.

### Claim 53 (depends on 49)

The method of claim 49, wherein the human CD34+ hematopoietic stem or progenitor cells are contacted with the culture medium comprising the lentiviral vector and 16,16-dimethyl PGE2 for at least four hours or for at least twenty-four hours.

### Claim 54 (depends on 49)

The method of claim 49, wherein the lentiviral vector comprises:
a) a left (5′) lentiviral LTR comprising a heterologous promoter;
b) an expression control sequence operably linked to a gene of interest; and
c) a right (3′) lentiviral SIN LTR.

### Claim 55 (depends on 49)

The method of claim 49, wherein the lentiviral vector comprises:
a) a left (5′) HIV-1 LTR comprising a CMV promoter;
b) a Psi packaging sequence (Ψ+);
c) an HIV-1 cPPT/FLAP;
d) an RRE;
e) a β-globin promoter and a β-globin LCR operably linked to a gene of interest; and
f) a right (3′) lentiviral SIN LTR that comprises
i) one or more insulator elements, or
ii) a rβgpA sequence.

### Claim 56 (depends on 49)

The method of claim 49, wherein the lentiviral vector comprises:
a) a left (5′) HIV-1 LTR comprising a CMV promoter;
b) a Psi (Ψ+) packaging signal;
c) a cPPT/FLAP;
d) an RRE;
e) an MND promoter, operably linked to a polynucleotide encoding a human ABCD1 polypeptide;
f) a right (3′) HIV-1 SIN LTR; and
g) a rβgpA sequence.
